Delcath Systems Inc
F:DV3R
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Delcath Systems Inc
F:DV3R
|
US |
|
U
|
Unimot SA
WSE:UNT
|
PL |
|
T
|
Teleperformance SE
XMUN:RCF
|
FR |
|
K
|
Kakao Games Corp
KOSDAQ:293490
|
KR |
Intrinsic Value
Is DV3R undervalued or overvalued?
See the intrinsic value estimate for 
Delcath Systems Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Delcath Systems Does
Delcath Systems makes a liver-directed cancer treatment called the HEPZATO KIT, along with the procedures and disposable components used to deliver it. Its core idea is to isolate the liver during treatment so a chemotherapy drug can be delivered at high dose to liver tumors while limiting exposure to the rest of the body. The company’s work sits at the intersection of medical devices, specialty drugs, and hospital procedure support.
- Headquarters
- United States of America US
- Employees
- 156
- IPO date
- Oct 19, 2000
Delcath Systems has no economic moat
Delcath Systems Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Revenue & Expenses Breakdown
Delcath Systems Inc
Earnings Waterfall
Delcath Systems Inc
The intrinsic value for Delcath Systems Inc (DV3R) under the Base Case is hidden EUR.
Compared with the current market price of 13.095 EUR, the stock appears hidden.